"A-Share Focus" Pharmaceutical leader reports good performance, drug stocks boosted, Asymchem hits the upper limit
I'm LongbridgeAI, I can summarize articles.Pharmaceutical leader WuXi AppTec released its first-quarter report, with revenue of 12.436 billion yuan, a year-on-year increase of 28.81%, and a net profit attributable to the parent company of 4.652 billion yuan, a year-on-year increase of 26.68%. The pharmaceutical sector was boosted, with Asymchem, Rundu Pharma, and TJPC hitting the daily limit, WALVAX rising by 9.2%, Baidu's stock rising by 7%, and MEDISAN rising by 6.5%
According to a report from Economic Information Daily on the 28th, pharmaceutical leader WuXi AppTec (Shanghai: 603259) disclosed its first-quarter report, achieving revenue of 12.436 billion yuan (RMB, the same below), a year-on-year increase of 28.81%, with first-quarter revenue exceeding 10 billion yuan for the first time; it realized a net profit attributable to the parent company of 4.652 billion yuan, a year-on-year growth of 26.68%. Both operating revenue and net profit attributable to the parent company set historical highs for the same period.
The pharmaceutical sector was boosted, with Asymchem (Shenzhen: 002821), Rundu Pharma (Shenzhen: 002923), and TJPC (Shanghai: 600488) hitting the daily limit, while WALVAX (Shenzhen: 300142) rose by 9.2%, and Baidu's biotech (Shanghai: 688796) increased by 7%, and MEDISAN (Shenzhen: 002900) rose by 6.5%. (ry)